MeSH term
Frequency | Condition_Probility | Adolescent | 26 | 0.0 |
Humans | 522 | 0.0 |
Lung/radiography | 2 | 7.0 |
Male | 200 | 0.0 |
Aged | 102 | 0.0 |
Female | 203 | 0.0 |
Middle Aged | 151 | 0.0 |
Antigens, CD/blood | 4 | 1.0 |
Cytokines/*pharmacology | 10 | 2.0 |
Interleukin-3/pharmacology | 7 | 2.0 |
Ploidies | 2 | 0.0 |
Recombinant Proteins/pharmacology | 22 | 1.0 |
Research Support, Non-U.S. Gov't | 306 | 0.0 |
Thrombopoietin/*pharmacology | 3 | 3.0 |
Adult | 154 | 0.0 |
Base Sequence | 36 | 0.0 |
DNA Primers | 7 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Genotype | 28 | 0.0 |
Interleukin-1/*genetics | 8 | 9.0 |
Phenotype | 16 | 0.0 |
Polymerase Chain Reaction | 19 | 0.0 |
*Polymorphism, Genetic | 15 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Blood Pressure | 2 | 0.0 |
Body Composition | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Comparative Study | 70 | 0.0 |
Cytokines/*physiology | 8 | 4.0 |
Endothelium, Vascular/*physiopathology | 2 | 2.0 |
Interleukin-6/blood | 29 | 6.0 |
Lipoproteins, HDL Cholesterol/blood | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
Sex Characteristics | 3 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 16 | 3.0 |
Animals | 115 | 0.0 |
Cell Division/drug effects | 27 | 0.0 |
Cell Line | 34 | 0.0 |
Interleukin-12/biosynthesis | 3 | 3.0 |
Interleukin-6/biosynthesis | 20 | 8.0 |
Mice | 61 | 0.0 |
Mice, Inbred BALB C | 8 | 0.0 |
English Abstract | 51 | 0.0 |
Culture Media | 6 | 0.0 |
Interleukin-1/*pharmacology | 11 | 2.0 |
Interleukin-6/*pharmacology | 9 | 4.0 |
RNA, Messenger/analysis | 14 | 0.0 |
Tumor Cells, Cultured | 42 | 0.0 |
Cytokines/blood | 6 | 2.0 |
Lymphocytes/*immunology | 2 | 0.0 |
*Renal Dialysis | 3 | 0.0 |
Time Factors | 26 | 0.0 |
Aged, 80 and over | 29 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Case-Control Studies | 19 | 0.0 |
Cell Culture Techniques | 9 | 1.0 |
Cell Differentiation/drug effects | 13 | 1.0 |
Hemodynamic Processes/*physiology | 2 | 6.0 |
Interleukin-1/*blood | 2 | 3.0 |
Interleukin-6/*blood | 22 | 7.0 |
Prospective Studies | 19 | 0.0 |
Severity of Illness Index | 8 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis | 12 | 4.0 |
African Americans | 2 | 1.0 |
*Alleles | 3 | 0.0 |
Cohort Studies | 8 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Homozygote | 4 | 0.0 |
Interleukin-6/*genetics | 19 | 27.0 |
Polymorphism, Genetic | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 58 | 0.0 |
Biological Markers/blood | 14 | 1.0 |
Heart Transplantation/*immunology | 3 | 4.0 |
Immunohistochemistry | 16 | 0.0 |
RNA, Messenger/*metabolism | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Acute Disease | 12 | 0.0 |
Fetal Blood/*metabolism | 2 | 4.0 |
Infant, Newborn | 13 | 0.0 |
Neutrophils/pathology | 3 | 5.0 |
Pregnancy | 8 | 0.0 |
Antigens, CD34/analysis | 7 | 1.0 |
Cattle | 4 | 0.0 |
Cell Culture Techniques/*methods | 4 | 4.0 |
Cell Division | 22 | 0.0 |
Graft Survival | 2 | 0.0 |
Growth Substances/*pharmacology | 6 | 1.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 3 | 4.0 |
Mice, SCID | 6 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 5 | 0.0 |
Risk Factors | 18 | 0.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 29 | 0.0 |
Injections, Intravenous | 2 | 0.0 |
Cross-Sectional Studies | 4 | 0.0 |
Interleukin-1/metabolism | 3 | 1.0 |
Interleukin-6/metabolism | 7 | 3.0 |
Tumor Necrosis Factor-alpha/metabolism | 7 | 0.0 |
Antirheumatic Agents/*therapeutic use | 4 | 7.0 |
Arthritis, Rheumatoid/*blood/*drug therapy | 2 | 50.0 |
Blood Sedimentation | 4 | 2.0 |
C-Reactive Protein/analysis | 15 | 2.0 |
Pain Measurement | 2 | 2.0 |
Receptors, Tumor Necrosis Factor/*therapeutic use | 2 | 5.0 |
Statistics, Nonparametric | 9 | 0.0 |
Cytokines/*blood | 23 | 7.0 |
Interleukins/blood | 4 | 10.0 |
Interleukin-6/*genetics/physiology | 2 | 50.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Herpesvirus 4, Human/physiology | 2 | 6.0 |
Lymphocyte Activation/*drug effects | 4 | 1.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Recombinant Fusion Proteins/pharmacology | 4 | 4.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Transfection | 13 | 0.0 |
Administration, Intravesical | 3 | 11.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
BCG Vaccine/*therapeutic use | 2 | 11.0 |
Combined Modality Therapy | 6 | 0.0 |
Cytokines/*urine | 2 | 50.0 |
Disease Progression | 12 | 0.0 |
*Immunotherapy | 3 | 1.0 |
Interleukin-2/urine | 2 | 66.0 |
Interleukin-6/urine | 3 | 75.0 |
Treatment Outcome | 7 | 0.0 |
Tumor Necrosis Factor-alpha/urine | 3 | 75.0 |
DNA Primers/chemistry | 3 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 9 | 1.0 |
Cytokines/*biosynthesis | 11 | 2.0 |
Hydrocortisone/blood | 4 | 0.0 |
Interferon Type II/secretion | 2 | 1.0 |
Interleukin-10/secretion | 2 | 6.0 |
Interleukin-6/secretion | 5 | 8.0 |
Pilot Projects | 4 | 0.0 |
Reference Values | 16 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 5 | 4.0 |
Biological Markers/analysis | 4 | 0.0 |
Interleukins/metabolism | 2 | 6.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Antibodies, Viral/blood | 3 | 2.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Cytokines/biosynthesis | 9 | 1.0 |
Lymphocyte Activation | 15 | 0.0 |
United States | 2 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Interleukin-1/pharmacology | 6 | 0.0 |
Interleukin-6/pharmacology | 17 | 6.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
Cytokines/pharmacology | 14 | 3.0 |
Membrane Proteins/pharmacology | 3 | 6.0 |
Mice, Inbred NOD | 3 | 1.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Thrombopoietin/pharmacology | 2 | 3.0 |
Flow Cytometry | 21 | 0.0 |
Immunophenotyping | 11 | 0.0 |
Monocytes/*immunology | 6 | 1.0 |
Phagocytosis | 2 | 0.0 |
Blotting, Northern | 13 | 0.0 |
Culture Techniques | 3 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
Interleukin-6/*analysis | 5 | 13.0 |
Probability | 2 | 0.0 |
Prognosis | 19 | 0.0 |
RNA, Messenger/*analysis | 5 | 1.0 |
Receptors, Interleukin-6/*analysis | 2 | 66.0 |
Sensitivity and Specificity | 11 | 0.0 |
Antigens, CD/analysis | 6 | 0.0 |
Interleukin-1/analysis | 4 | 4.0 |
Interleukin-10/analysis | 2 | 5.0 |
Interleukin-6/analysis | 9 | 11.0 |
Receptors, Tumor Necrosis Factor, Type I | 3 | 0.0 |
Exons | 7 | 0.0 |
Gene Frequency | 7 | 0.0 |
Haplotypes/*genetics | 3 | 1.0 |
Introns | 5 | 0.0 |
Apoptosis | 4 | 0.0 |
Leukocyte Count | 8 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Remission Induction | 2 | 0.0 |
Interleukin-6/blood/metabolism | 2 | 15.0 |
Neoplasm Metastasis | 4 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
APACHE | 2 | 3.0 |
Interleukin-1/blood/metabolism | 2 | 33.0 |
Cells, Cultured | 77 | 0.0 |
Interferon Type II/genetics | 6 | 7.0 |
Interleukin-1/genetics | 3 | 4.0 |
Interleukin-6/genetics | 9 | 13.0 |
Interleukin-8/genetics | 2 | 3.0 |
Tumor Necrosis Factor-alpha/genetics | 8 | 3.0 |
Analysis of Variance | 8 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 7 | 2.0 |
Double-Blind Method | 8 | 0.0 |
Homeostasis | 3 | 0.0 |
Infusions, Intravenous | 3 | 0.0 |
Lymphocyte Count | 2 | 0.0 |
Chi-Square Distribution | 5 | 0.0 |
Child | 18 | 0.0 |
Chronic Disease | 10 | 0.0 |
Cytokines/*genetics | 9 | 6.0 |
Cytokines/*metabolism | 6 | 2.0 |
Interleukin-6/*metabolism | 11 | 10.0 |
Prostatic Neoplasms/*metabolism | 2 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Anti-Inflammatory Agents/therapeutic use | 2 | 2.0 |
Lipopolysaccharides/pharmacology | 13 | 1.0 |
Lymphocyte Activation/drug effects | 7 | 1.0 |
B-Lymphocytes/*immunology | 5 | 0.0 |
Interleukin-6/*immunology | 2 | 16.0 |
Endothelin-1/*blood | 2 | 9.0 |
Biopsy | 5 | 0.0 |
Pancreatic Elastase/analysis | 2 | 11.0 |
Cats | 2 | 0.0 |
Interleukin-10/biosynthesis | 6 | 5.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 15 | 2.0 |
Bone Density/*genetics | 2 | 1.0 |
Haplotypes | 6 | 0.0 |
Linkage Disequilibrium | 4 | 0.0 |
Osteoporosis/etiology/genetics | 2 | 66.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Cytokines/*genetics/metabolism | 3 | 18.0 |
DNA/genetics | 3 | 0.0 |
Germany | 2 | 0.0 |
Interleukin-10/genetics | 2 | 4.0 |
Interleukin-2/genetics | 3 | 3.0 |
Multivariate Analysis | 4 | 0.0 |
Random Allocation | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Genetic Markers | 4 | 0.0 |
Inflammation | 4 | 1.0 |
Models, Biological | 3 | 0.0 |
Rats | 17 | 0.0 |
B-Lymphocytes/cytology/drug effects/metabolism | 2 | 33.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/*drug effects/immunology/metabolism | 2 | 25.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Anti-Bacterial Agents/therapeutic use | 2 | 1.0 |
Cytokines/immunology | 2 | 1.0 |
Culture Media/pharmacology | 2 | 2.0 |
Interleukin-3/*pharmacology | 3 | 2.0 |
Alzheimer Disease/metabolism | 2 | 3.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Interferon Type II/biosynthesis | 7 | 1.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology | 5 | 0.0 |
Intercellular Adhesion Molecule-1/blood | 3 | 3.0 |
Interferon Type II/blood | 4 | 3.0 |
Interleukin-1/blood | 8 | 4.0 |
Interleukin-2/blood | 2 | 2.0 |
Receptors, Interleukin-2/blood | 4 | 5.0 |
T-Lymphocytes/immunology | 5 | 0.0 |
*HIV-1 | 3 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Age Factors | 6 | 0.0 |
Alleles | 14 | 0.0 |
Echocardiography | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Transforming Growth Factor beta/biosynthesis | 2 | 4.0 |
Biological Markers | 9 | 0.0 |
C-Reactive Protein/metabolism | 4 | 1.0 |
Netherlands | 2 | 1.0 |
Predictive Value of Tests | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 5 | 1.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Cell Separation | 4 | 0.0 |
Coculture Techniques | 3 | 0.0 |
Colony-Forming Units Assay | 7 | 1.0 |
Fetal Blood/*cytology | 3 | 1.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 4 | 2.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 6 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Stromal Cells/cytology | 3 | 6.0 |
Disease Models, Animal | 5 | 0.0 |
Gene Expression | 14 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Sialoglycoproteins/genetics | 2 | 6.0 |
Cell Survival/drug effects | 4 | 0.0 |
Drug Combinations | 2 | 0.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 8 | 0.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 6 | 1.0 |
Immunization | 3 | 0.0 |
Leukocytes, Mononuclear/*immunology | 3 | 1.0 |
Receptors, Interleukin-6/*blood | 2 | 15.0 |
Solubility | 8 | 0.0 |
Receptors, Interleukin-2/*blood | 2 | 3.0 |
Blood Gas Analysis | 2 | 5.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 5 | 0.0 |
Interleukin-1/biosynthesis | 7 | 3.0 |
Antigen-Presenting Cells/physiology | 2 | 3.0 |
Regression Analysis | 3 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 2 | 3.0 |
*Hematopoiesis | 4 | 2.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Interleukin-6/*physiology | 15 | 18.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Tumor Necrosis Factor-alpha/*physiology | 4 | 1.0 |
Th1 Cells/*immunology | 3 | 2.0 |
Th2 Cells/*immunology | 3 | 2.0 |
Arthroscopy | 2 | 18.0 |
Cell Count | 4 | 0.0 |
Interleukin-6/analysis/*biosynthesis | 2 | 33.0 |
Tumor Necrosis Factor-alpha/analysis/*biosynthesis | 2 | 11.0 |
Cytokines/*secretion | 8 | 13.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/secretion | 2 | 12.0 |
In Vitro | 30 | 0.0 |
Interleukin-1/secretion | 3 | 7.0 |
Age Distribution | 2 | 0.0 |
Child, Preschool | 16 | 0.0 |
Infant | 10 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Survival Analysis | 5 | 0.0 |
*Antiretroviral Therapy, Highly Active | 2 | 0.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
HIV Infections/*drug therapy/genetics | 2 | 28.0 |
HIV-1/*genetics | 2 | 0.0 |
RNA, Viral/blood | 2 | 0.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Viral Load | 4 | 0.0 |
Viremia/*genetics | 2 | 100.0 |
Hematopoiesis | 3 | 1.0 |
Platelet Count | 3 | 0.0 |
Polyethylene Glycols/*pharmacology | 2 | 7.0 |
Stimulation, Chemical | 9 | 1.0 |
Cytokines/metabolism | 5 | 1.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Hela Cells | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Cholesterol/blood | 2 | 0.0 |
Antibodies, Antinuclear/blood | 2 | 4.0 |
China | 2 | 0.0 |
Interleukin-6/biosynthesis/immunology | 3 | 37.0 |
Phytohemagglutinins/pharmacology | 5 | 0.0 |
Glycoproteins/genetics | 2 | 2.0 |
Cytokines/physiology | 6 | 3.0 |
Inflammation/physiopathology | 2 | 3.0 |
Signal Transduction | 6 | 0.0 |
Italy | 3 | 0.0 |
Seasons | 2 | 1.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Corticotropin/blood | 3 | 1.0 |
Recurrence | 6 | 0.0 |
*Blood Coagulation | 2 | 0.0 |
P-Selectin/blood | 2 | 3.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
*Cell Division | 2 | 1.0 |
Hematopoietic Stem Cells/*cytology/immunology | 2 | 2.0 |
Neoplasms/pathology | 2 | 7.0 |
Bronchoalveolar Lavage Fluid/chemistry | 2 | 3.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Culture Media, Conditioned | 2 | 0.0 |
Kinetics | 15 | 0.0 |
Immune Tolerance | 3 | 1.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Survival Rate | 6 | 0.0 |
Trauma Severity Indices | 2 | 11.0 |
DNA/biosynthesis | 2 | 0.0 |
Lipopolysaccharides/*pharmacology | 5 | 1.0 |
Receptors, IgE/blood | 2 | 25.0 |
Blotting, Southern | 5 | 0.0 |
Blotting, Western | 5 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Body Weight | 3 | 0.0 |
Mice, Nude | 7 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Orosomucoid/analysis | 2 | 4.0 |
Cardiopulmonary Bypass/*adverse effects | 2 | 7.0 |
Cell Adhesion | 4 | 0.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
C-Reactive Protein/*analysis | 5 | 1.0 |
Diagnosis, Differential | 5 | 0.0 |
Macrophage Activation | 4 | 2.0 |
Blood Cell Count | 2 | 0.0 |
*Inflammation | 3 | 8.0 |
Lymphocyte Subsets | 3 | 1.0 |
Cytokines/analysis | 3 | 4.0 |
*Cytotoxicity, Immunologic | 5 | 1.0 |
Follow-Up Studies | 6 | 0.0 |
Interleukin-6/*analysis/blood | 2 | 20.0 |
Enzyme-Linked Immunosorbent Assay/methods | 6 | 2.0 |
Neopterin/blood | 2 | 7.0 |
Age of Onset | 2 | 0.0 |
Glucose Tolerance Test | 2 | 0.0 |
Fibroblasts/metabolism | 5 | 0.0 |
Interleukin-6/genetics/metabolism | 3 | 12.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 8 | 0.0 |
Karyotyping | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Interleukin-6/immunology | 3 | 10.0 |
Tumor Necrosis Factor-alpha/immunology | 4 | 3.0 |
Interferon Type II/analysis | 2 | 2.0 |
Megakaryocytes/*pathology | 2 | 6.0 |
*Plasmapheresis | 2 | 6.0 |
Receptors, Tumor Necrosis Factor/blood | 2 | 2.0 |
Calcitonin/*blood | 4 | 6.0 |
Protein Precursors/*blood | 4 | 5.0 |
Inflammation Mediators/metabolism/*physiology | 2 | 66.0 |
*Graft Rejection | 2 | 2.0 |
Swine | 3 | 0.0 |
Postoperative Period | 2 | 0.0 |
Depression/blood/*immunology | 2 | 66.0 |
Quality of Life | 2 | 1.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Gene Expression/drug effects | 5 | 0.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Interleukin-6/pharmacology/*physiology | 2 | 18.0 |
Lymphokines/*pharmacology | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 8 | 1.0 |
*Linkage (Genetics) | 2 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Incidence | 2 | 0.0 |
Cytokines/genetics/*metabolism | 2 | 5.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Interleukin-6/biosynthesis/metabolism | 3 | 42.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Half-Life | 2 | 0.0 |
*Muscle Proteins | 2 | 0.0 |
Antibodies/blood | 2 | 3.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Interleukin-6/*biosynthesis | 20 | 18.0 |
Cell Division/immunology | 2 | 0.0 |
HIV Infections/immunology | 2 | 2.0 |
*Postmenopause | 2 | 3.0 |
Binding Sites | 7 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Molecular Sequence Data | 34 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Inflammation/*physiopathology | 2 | 3.0 |
*Cardiopulmonary Bypass | 2 | 2.0 |
Monocytes/physiology | 2 | 1.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Interleukin-2/biosynthesis | 3 | 0.0 |
Interleukin-4/biosynthesis | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
Chromosome Mapping | 8 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Interleukins/biosynthesis | 3 | 6.0 |
Receptors, IgG/*immunology | 2 | 6.0 |
HIV Core Protein p24/biosynthesis | 2 | 4.0 |
Interleukin-4/*pharmacology | 9 | 4.0 |
Interleukin-8/*biosynthesis | 4 | 6.0 |
Virus Replication | 6 | 0.0 |
Interleukin-8/biosynthesis | 3 | 2.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Cell Communication | 3 | 1.0 |
Drug Synergism | 9 | 0.0 |
*Herpesvirus 4, Human | 3 | 8.0 |
Interleukin-2/*blood | 2 | 9.0 |
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 8.0 |
Cloning, Molecular | 10 | 0.0 |
Fibroblast Growth Factor 2/*pharmacology | 2 | 1.0 |
Transforming Growth Factor beta/*pharmacology | 3 | 0.0 |
Cell Differentiation | 14 | 0.0 |
Endothelium, Vascular/cytology/*physiology | 2 | 3.0 |
Antigens, CD28/immunology | 3 | 2.0 |
Antigens, CD3/immunology | 2 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
Monocytes/immunology | 5 | 1.0 |
Cytokines/*analysis | 7 | 8.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Hemodynamic Processes | 2 | 1.0 |
Dogs | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Swine/*genetics | 3 | 2.0 |
Acid Phosphatase/metabolism | 2 | 3.0 |
Cell Adhesion/drug effects | 4 | 0.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Inflammation Mediators/*blood | 2 | 4.0 |
Biological Assay | 3 | 1.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Cytokines | 3 | 2.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha | 3 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Hamsters | 2 | 0.0 |
*Interleukin-6 | 2 | 0.0 |
Immunotherapy | 3 | 0.0 |
Neoplasm Proteins/*biosynthesis | 3 | 3.0 |
Amino Acid Sequence | 12 | 0.0 |
Cell Division/physiology | 4 | 0.0 |
Cell Transformation, Viral/physiology | 2 | 33.0 |
Proteins/metabolism/*physiology | 2 | 4.0 |
CCAAT-Enhancer-Binding Proteins | 3 | 1.0 |
Oligonucleotide Probes | 4 | 0.0 |
Plasmids | 4 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Endotoxins/*blood | 2 | 5.0 |
*Bone Marrow Cells | 3 | 1.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Leukocytes, Mononuclear/chemistry | 2 | 7.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
B-Lymphocytes/immunology | 6 | 0.0 |
Mice, Inbred C3H | 3 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Monocytes/metabolism | 3 | 0.0 |
B-Lymphocytes/*drug effects | 2 | 10.0 |
Cell Line, Transformed | 3 | 0.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Megakaryocytes/*cytology | 3 | 5.0 |
Immunotherapy/*methods | 3 | 2.0 |
Urine/cytology | 3 | 27.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Killer Cells, Natural/*immunology | 3 | 0.0 |
Cytokines/*immunology | 2 | 2.0 |
Interferon Type II/immunology | 2 | 2.0 |
Vaccination | 3 | 1.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Interleukins/*biosynthesis | 2 | 8.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Antigens, CD14/blood | 2 | 6.0 |
Bone Density | 2 | 1.0 |
Cytokines/*biosynthesis/immunology | 2 | 15.0 |
Macrophages/immunology | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Heterozygote | 2 | 0.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Interleukin-6/*biosynthesis/*pharmacology | 2 | 100.0 |
Interferons/pharmacology | 2 | 2.0 |
Interleukins/pharmacology | 3 | 4.0 |
Tumor Necrosis Factor-alpha/pharmacology | 10 | 0.0 |
Cell Survival | 3 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Hybrid Cells | 6 | 0.0 |
Hematopoiesis/*physiology | 2 | 2.0 |
Receptors, Cytokine/*analysis | 2 | 12.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Interleukin-6/*secretion | 3 | 8.0 |
Fever/*physiopathology | 2 | 18.0 |
Interleukin-8/blood | 2 | 2.0 |
Cell Division/radiation effects | 2 | 4.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Ligands | 3 | 0.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Immunity, Cellular | 5 | 0.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Antibodies/pharmacology | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Herpesvirus 4, Human/*isolation & purification | 2 | 5.0 |
Gestational Age | 2 | 0.0 |
Receptors, Interleukin-6 | 16 | 19.0 |
DNA Probes | 3 | 0.0 |
Culture Techniques/methods | 2 | 3.0 |
Organ Specificity | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Cytochrome P-450 CYP2B1 | 2 | 50.0 |
Liver/*drug effects/enzymology | 2 | 4.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Cytokines/*therapeutic use | 2 | 11.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Peptides/*pharmacology | 2 | 0.0 |
Pertussis Toxin | 2 | 1.0 |
Radioimmunoassay | 2 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Lipopolysaccharides/*immunology | 2 | 2.0 |
Precipitin Tests | 3 | 0.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Interleukin-2/biosynthesis/pharmacology | 3 | 14.0 |
Pokeweed Mitogens/pharmacology | 2 | 2.0 |
Antigens, CD/genetics | 2 | 1.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 3 | 6.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Interleukin-2/*pharmacology | 4 | 1.0 |
Transplantation, Homologous | 4 | 0.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 2 | 0.0 |
*Bacterial Toxins | 3 | 2.0 |
*Genes, Structural | 2 | 0.0 |
Receptor, Ciliary Neurotrophic Factor | 2 | 2.0 |
Restriction Mapping | 5 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Immunoglobulin G/*biosynthesis | 3 | 8.0 |
Lymphocyte Cooperation | 2 | 2.0 |
Ciliary Neurotrophic Factor | 2 | 1.0 |
B-Lymphocytes/*cytology/immunology | 2 | 6.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
RNA, Viral/analysis | 2 | 0.0 |
Clone Cells | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Epithelial Cells | 6 | 1.0 |
*Glycoproteins | 3 | 0.0 |
Interleukin-4/blood | 2 | 4.0 |
Bone and Bones/*metabolism | 2 | 2.0 |
*Gene Expression | 3 | 0.0 |
Interleukin-1/*biosynthesis | 3 | 2.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Interleukin-6/*genetics/metabolism | 2 | 40.0 |
*Gene Expression Regulation | 2 | 0.0 |
Cytokines/*biosynthesis/genetics/secretion | 2 | 100.0 |
Macrophages/*immunology | 3 | 1.0 |
3T3 Cells | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Interleukin-1/*physiology | 3 | 3.0 |
Calcitriol/blood | 2 | 4.0 |
Stem Cell Factor | 2 | 2.0 |
Interleukin-6/*biosynthesis/genetics/isolation & purification | 2 | 100.0 |
Carrier State | 2 | 7.0 |
Influenza Vaccines/*immunology | 2 | 10.0 |
Lymphocytes/immunology | 3 | 0.0 |
HIV Infections/*immunology | 2 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Antigens, CD14 | 3 | 1.0 |
Antigens, Differentiation, Myelomonocytic/immunology | 2 | 4.0 |
Epithelium/metabolism | 4 | 1.0 |
Antigens, CD/*analysis | 3 | 0.0 |
Antigens, CD34 | 2 | 0.0 |
*Chimeric Proteins | 4 | 40.0 |
Mutation | 2 | 0.0 |
Virus Replication/drug effects | 2 | 0.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Liver Neoplasms | 2 | 0.0 |
Interleukin-6/*biosynthesis/blood | 2 | 20.0 |
Phytohemagglutinins | 2 | 2.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
Receptors, Interleukin-2/metabolism | 2 | 1.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Receptors, Interleukin-2/analysis | 3 | 1.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Astrocytoma | 2 | 5.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
Lipopolysaccharides | 3 | 2.0 |
*Growth Inhibitors | 2 | 3.0 |
*Acute-Phase Reaction | 2 | 9.0 |
Receptors, Immunologic/physiology | 2 | 1.0 |
Interleukin-2/physiology | 2 | 2.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Interleukin-2/pharmacology | 7 | 1.0 |
*Chromosomes, Human, Pair 5 | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Interleukins/*genetics | 3 | 10.0 |
*Down-Regulation | 2 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Interleukin-6/administration & dosage/*pharmacology | 3 | 50.0 |
Anthranilic Acids/*pharmacology | 2 | 33.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Anemia/*blood/etiology | 2 | 14.0 |
Arthritis, Rheumatoid/*blood/complications | 2 | 18.0 |
Transcobalamins/*analysis | 2 | 40.0 |
Longitudinal Studies | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
*ADP Ribose Transferases | 3 | 3.0 |
Pseudomonas | 2 | 40.0 |
*Virulence Factors | 3 | 3.0 |
Immune Sera | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Immunoassay | 2 | 0.0 |
Interleukin-6/pharmacology/*secretion | 2 | 100.0 |
Recombinant Proteins | 5 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 2 | 1.0 |
Immunoglobulin E/biosynthesis | 2 | 5.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Receptors, IgE | 2 | 3.0 |
Antigens, CD3 | 3 | 0.0 |
*Gene Expression Regulation, Fungal | 2 | 4.0 |
Antigens, CD57 | 2 | 3.0 |
Antigens, CD8 | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 2 | 0.0 |
Rats, Inbred F344 | 3 | 0.0 |
Interleukin-1/physiology | 2 | 2.0 |
Guinea Pigs | 2 | 0.0 |
Interleukin-6 | 9 | 20.0 |
Cell Survival/*drug effects | 3 | 3.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Down-Regulation | 2 | 0.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Chimera | 2 | 1.0 |
Interferon Type I, Recombinant/*pharmacology | 2 | 4.0 |
*Protein Biosynthesis | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Interleukin-4 | 3 | 3.0 |
Interleukin-5 | 2 | 15.0 |
Monokines | 2 | 11.0 |
Interleukins/*pharmacology | 4 | 5.0 |
Lymphokines/analysis | 2 | 2.0 |
Interleukin-10/*genetics | 3 | 6.0 |
Biological Markers/*blood | 2 | 1.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Blood Glucose/analysis | 2 | 0.0 |
